10.1016/s1473-3099(23)00393-6 - Safety and efficacy of inhaled IBIO12...

This document has been corrected

Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial

10.1016/s1473-3099(23)00393-6

Published Online: 2024-01-?

Journal: The Lancet Infectious Diseases•Publisher: Elsevier BV

Authors: Alexandre Fugère•Andrés Finzi•Annie Leroux•Bruno Maranda•Djordje Grbic•Frédéric Leduc•Jean-François Larrivée•Magali Lurquin•Pascal Brabant•Simon Gaudreau•Sébastien M Labbé•Yolandi Swart

This document has been corrected

Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial

10.1016/s1473-3099(23)00393-6

Published Online: 2024-01-?

Journal: The Lancet Infectious Diseases

NOW

2023-11-01•Erratum

Correction to Lancet Infect Dis 2023; published online Aug 21. https://doi.org/10.1016/S1473-3099(23)00393-6

10.1016/s1473-3099(23)00628-x

* information provided by CrossRef

2023-11-01•Erratum

10.1016/s1473-3099(23)00628-x

* information provided by CrossRef

2024-01-?•Published

2023-11-01•Erratum

Correction to Lancet Infect Dis 2023; published online Aug 21. https://doi.org/10.1016/S1473-3099(23)00393-6

10.1016/s1473-3099(23)00628-x

* information provided by CrossRef

This document has been corrected

Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial

10.1016/s1473-3099(23)00393-6

Published Online: 2024-01-?

Journal: The Lancet Infectious Diseases•Publisher: Elsevier BV